Literature DB >> 22912546

Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.

Chariya Hahnvajanawong1, Jariya Chaiyagool, Wunchana Seubwai, Vajarabhongsa Bhudhisawasdi, Nisana Namwat, Narong Khuntikeo, Banchob Sripa, Ake Pugkhem, Wichittra Tassaneeyakul.   

Abstract

AIM: To determine whether expression of certain enzymes related to 5-fluorouracil (5-FU) metabolism predicts 5-FU chemosensitivity in cholangiocarcinoma (CCA).
METHODS: The histoculture drug response assay (HDRA) was performed using surgically resected CCA tissues. Tumor cell viability was determined morphologically with hematoxylin and eosin- and terminal deoxynucleotide transferase-mediated dUTP nick-end labeling-stained tissues. The mRNA expression of thymidine phosphorylase (TP), orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) was determined with real-time reverse transcriptase-polymerase chain reaction. The levels of gene expression and the sensitivity to 5-FU were evaluated.
RESULTS: Twenty-three CCA tissues were obtained from patients who had been diagnosed with intrahepatic CCA and who underwent surgical resection at Srinagarind Hospital, Khon Kaen University from 2007 to 2009. HDRA was used to determine the response of these CCA tissues to 5-FU. Based on the dose-response curve, 200 μg/mL 5-FU was selected as the test concentration. The percentage of inhibition index at the median point was selected as the cut-off point to differentiate the responding and non-responding tumors to 5-FU. When the relationship between TP, OPRT, TS and DPD mRNA expression levels and the sensitivity of CCA tissues to 5-FU was examined, only OPRT mRNA expression was significantly correlated with the response to 5-FU. The mean expression level of OPRT was significantly higher in the responder group compared to the non-responder group (0.41 ± 0.25 vs 0.22 ± 0.12, P < 0.05).
CONCLUSION: OPRT mRNA expression may be a useful predictor of 5-FU chemosensitivity of CCA. Whether OPRT mRNA could be used to predict the success of 5-FU chemotherapy in CCA patients requires confirmation in patients.

Entities:  

Keywords:  5-fluorouracil; Chemosensitivity; Cholangiocarcinoma; Histoculture drug response assay; Orotate phosphoribosyl transferase

Mesh:

Substances:

Year:  2012        PMID: 22912546      PMCID: PMC3419992          DOI: 10.3748/wjg.v18.i30.3955

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?

Authors:  C J Allegra
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 2.  The role of chemotherapy in cholangiocarcinoma.

Authors:  S Thongprasert
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

3.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.

Authors:  Carmen J Allegra; Allyson L Parr; Lester E Wold; Michelle R Mahoney; Daniel J Sargent; Patrick Johnston; Pam Klein; Katie Behan; Michael J O'Connell; Ralph Levitt; John W Kugler; Maria Tria Tirona; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

5.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

Authors:  C G Leichman; H J Lenz; L Leichman; K Danenberg; J Baranda; S Groshen; W Boswell; R Metzger; M Tan; P V Danenberg
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

6.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

7.  Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.

Authors:  Tao Ma; Zheng-Gang Zhu; Yu-Bao Ji; Yi Zhang; Ying-Yan Yu; Bing-Ya Liu; Hao-Ran Yin; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

8.  Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.

Authors:  M P Findlay; D Cunningham; G Morgan; S Clinton; A Hardcastle; G W Aherne
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.

Authors:  K Yamaguchi; Y Arai; Y Kanda; K Akagi
Journal:  Jpn J Cancer Res       Date:  2001-03

10.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors:  W Ichikawa; H Uetake; Y Shirota; H Yamada; T Takahashi; Z Nihei; K Sugihara; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more
  9 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.

Authors:  Shenli Zhang; Iain B Tan; Nur S Sapari; Heike I Grabsch; Alicia Okines; Elizabeth C Smyth; Toru Aoyama; Lindsay C Hewitt; Imran Inam; Dan Bottomley; Matthew Nankivell; Sally P Stenning; David Cunningham; Andrew Wotherspoon; Akira Tsuburaya; Takaki Yoshikawa; Richie Soong; Patrick Tan
Journal:  J Mol Diagn       Date:  2015-03-04       Impact factor: 5.568

3.  Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.

Authors:  Shuhan Lin; Hao Lai; Yuzhou Qin; Jiansi Chen; Yuan Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 5.  Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma.

Authors:  Massimiliano Cadamuro; Simone Brivio; Carlo Spirli; Ruth E Joplin; Mario Strazzabosco; Luca Fabris
Journal:  Int J Mol Sci       Date:  2017-01-13       Impact factor: 5.923

Review 6.  Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models.

Authors:  Qingfan Zheng; Bin Zhang; Changfeng Li; Xuewen Zhang
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

7.  Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines.

Authors:  Somphon Roeksomtawin; Panida Navasumrit; Somchamai Waraprasit; Varabhorn Parnlob; Thaniya Sricharunrat; Vajarabhongsa Bhudhisawasdi; Niramol Savaraj; Mathuros Ruchirawat
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

Review 8.  Current and novel therapeutic opportunities for systemic therapy in biliary cancer.

Authors:  José J G Marin; Maria Giuseppina Prete; Angela Lamarca; Simona Tavolari; Ana Landa-Magdalena; Giovanni Brandi; Oreste Segatto; Arndt Vogel; Rocío I R Macias; Pedro M Rodrigues; Adelaida La Casta; Joachim Mertens; Cecilia M P Rodrigues; Maite G Fernandez-Barrena; Ana Da Silva Ruivo; Marco Marzioni; Giulia Mentrasti; Pilar Acedo; Patricia Munoz-Garrido; Vincenzo Cardinale; Jesus M Banales; Juan W Valle; John Bridgewater; Chiara Braconi
Journal:  Br J Cancer       Date:  2020-07-22       Impact factor: 7.640

Review 9.  Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance.

Authors:  Jose J G Marin; Paula Sanchon-Sanchez; Candela Cives-Losada; Sofía Del Carmen; Jesús M González-Santiago; Maria J Monte; Rocio I R Macias
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.